Wide Ranks

ICCC

ImmuCell Corporation

3.72

Top Statistics
Market Cap 33 M Forward PE -33.82 Revenue Growth 54.90 %
Current Ratio 2.37 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -17.44 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -67.40 Enterprise / Revenue 1.84 Price To Sales Trailing12 Months 1.43
Profitability
Profit Margins -17.44 % Operating Margins -25.34 %
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.1690 Total Debt 15 M
Total Debt To Equity 67.52 Current Ratio 2.37 Book Value Per Share 3.23
All Measures
Short Ratio 23.00 % Message Board Id finmb_29789 Shares Short Prior Month 11659
Return On Equity -0.1610 City Portland Uuid 537ec7af-c75b-32e2-b76f-a4455e4e4e57
Previous Close 3.76 First Trade Date Epoch Utc 547 M Book Value 3.23
Beta 0.5670 Total Debt 15 M Volume 14744
Price To Book 1.15 Last Split Date 648 M Fifty Two Week Low 3.34
Total Cash Per Share 0.1690 Total Revenue 23 M Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -25.34 %
Net Income To Common -4049325 Short Percent Of Float 0.0006 Implied Shares Outstanding 8 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 21210
Average Volume10days 21210 Total Cash 1 M Next Fiscal Year End 1 B
Revenue Per Share 2.99 Held Percent Insiders 0.3952 Ebitda Margins -2.73 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 3.76 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.61 Open 3.65 Free Cashflow 522355
State ME Dividend Yield 0.00 % Return On Assets -0.0487
Time Zone Short Name EST Trailing Eps -0.4900 Day Low 3.55
Address1 56 Evergreen Drive Shares Outstanding 8 M Price Hint 4
Target High Price 0.0000 Website https://immucell.com 52 Week Change -0.1806
Average Volume 32350 Forward Eps -0.1100 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 72.40 % Last Split Factor 1:100
Regular Market Day High 3.79 Is_sp_500 False Profit Margins -17.44 %
Debt To Equity 67.52 Fifty Two Week High 5.59 Day High 3.79
Shares Short 4009 Regular Market Open 3.65 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 1.84 Revenue Growth 54.90 %
Shares Percent Shares Out 0.0005 Operating Cashflow -230540 Currency USD
Time Zone Full Name America/New_York Market Cap 33 M Is_nasdaq_100 False
Zip 04103 Quote Type EQUITY Industry Biotechnology
Long Name ImmuCell Corporation Regular Market Day Low 3.55 Held Percent Institutions 0.1451
Current Price 3.72 Enterprise To Ebitda -67.40 Financial Currency USD
Current Ratio 2.37 Gross Margins 28.32 % Industry Disp Biotechnology
Country United States Float Shares 4 M Two Hundred Day Average 4.32
Ir Website http://www.immucell.com/ir-facts.html Enterprise Value 42 M Price To Sales Trailing12 Months 1.43
Forward PE -33.82 Regular Market Volume 14744 Ebitda -633697
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.

The company operates through two segments, Scours and Mastitis.

It offers First Defense, an orally delivered scours preventive product for calves with claims against E.

coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

coli, coronavirus, and rotavirus.

The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.

In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

It sells its products through animal health distributors.

ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.